WO2007135547A2 - Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis - Google Patents

Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis Download PDF

Info

Publication number
WO2007135547A2
WO2007135547A2 PCT/IB2007/001321 IB2007001321W WO2007135547A2 WO 2007135547 A2 WO2007135547 A2 WO 2007135547A2 IB 2007001321 W IB2007001321 W IB 2007001321W WO 2007135547 A2 WO2007135547 A2 WO 2007135547A2
Authority
WO
WIPO (PCT)
Prior art keywords
nonbacterial prostatitis
prostate
chronic nonbacterial
estrogen receptor
prostatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001321
Other languages
English (en)
French (fr)
Other versions
WO2007135547A3 (en
Inventor
Risto Santti
Tomi Streng
Kaija Halonen
Jenni Bernoulli
Emrah Yatkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hormos Medical Ltd
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES07734629.4T priority Critical patent/ES2551690T3/es
Priority to MX2008014825A priority patent/MX2008014825A/es
Priority to CA2652783A priority patent/CA2652783C/en
Priority to KR1020087030717A priority patent/KR101505884B1/ko
Priority to JP2009511598A priority patent/JP5123935B2/ja
Priority to BRPI0712103-2A priority patent/BRPI0712103A2/pt
Priority to AU2007252991A priority patent/AU2007252991B2/en
Priority to EP07734629.4A priority patent/EP2029128B1/en
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Priority to RU2008150489/15A priority patent/RU2480207C2/ru
Publication of WO2007135547A2 publication Critical patent/WO2007135547A2/en
Publication of WO2007135547A3 publication Critical patent/WO2007135547A3/en
Priority to NO20084822A priority patent/NO341185B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Definitions

  • the invention is directed to a method of treating men suffering from chronic nonbacterial prostatitis with a selective estrogen receptor modulator (SERM) compound, an aromatase inhibitor and/or an antiestrogen.
  • SERM selective estrogen receptor modulator
  • Prostatitis is an inflammatory disorder of the prostate, which close to 50 percent of all men suffer at some stage of their life.
  • Chronic nonbacterial prostatitis involves inflammation of the prostate gland and commonly affects men of all ages. It can cause chronic pelvic pain syndrome (CPPS), problems urinating, including discomfort and pain, increased frequency and urge, or problems emptying the bladder.
  • CPPS chronic pelvic pain syndrome
  • BPH benign prostatic hyperplasia
  • SERMs Selective estrogen receptor modulators
  • Compounds like tamoxifen, toremifene, raloxifene, lasofoxifene, apeledoxifene, ospemifene and f ⁇ spemifene are typical SERMs. They share some common characteristics such as being antiestrogenic in breast cancer and estrogenic in bone, whereas in other organs they show varying degrees of estrogenic or antiestrogenic properties. In the urinary tract, the antiestrogenic properties seem to prevail.
  • SERMs selective estrogen receptor modulators
  • LUTS lower urinary tract symptoms
  • the present invention is a method of treating chronic nonbacterial prostatitis in men, wherein the chronic nonbacterial prostatitis is not associated with urethral sphincter dysfunction.
  • the method comprises administering an effective amount of (i) a selective estrogen receptor modulator having antiestrogenic effect in the prostate, (ii) an aromatase inhibitor, and/or (iii) an anti-estrogen, to a patient in need thereof.
  • the invention is also a method of preventing the progression of BPH and, prostate cancer.
  • Development of stromal overgrowth (homologous to stromal overgrowth in human BPH) and development of prostate cancer are associated with long term duration of chronic prostatitis.
  • Treating the chronic prostatitis with SERMs, e.g. fispemifene, or aromatase inhibitors or antiestrogen will prevent progression of BPH or development of prostate cancer.
  • SERMs such as fispemifene
  • lowering of estrogen concentration in the body by using aromatase inhibitors, or by using anti-estrogens, can be used to treat this condition.
  • the prostate in these animals was larger than normal, exhibiting chronic prostatitis and precancerous lesions and ductal carcinomas of the prostate, suggestive of a trend toward development of BPH and prostate cancer.
  • a fourth group of rats was treated for 3 weeks with T (240 ug/day) and E2 (70 ug/day), and thereafter administered 2 doses of a pure estrogen antagonist fulvestrant (5mg/kg) on the third week. Fulvestrant significantly reduced the prostatitis compared to the control group treated with T and E2 only. As prostatitis can be reversed by administering an antiestrogen, the condition is seen to be estrogen dependent.
  • Suitable preparation forms include for example tablets, capsules, granules, powders, suspensions, and syrups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PCT/IB2007/001321 2006-05-22 2007-05-22 Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis Ceased WO2007135547A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2007252991A AU2007252991B2 (en) 2006-05-22 2007-05-22 Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
CA2652783A CA2652783C (en) 2006-05-22 2007-05-22 Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
KR1020087030717A KR101505884B1 (ko) 2006-05-22 2007-05-22 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
JP2009511598A JP5123935B2 (ja) 2006-05-22 2007-05-22 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
BRPI0712103-2A BRPI0712103A2 (pt) 2006-05-22 2007-05-22 método de tratamento de prostatite não bacteriana crÈnica e para impedir a progressão de hiperplasia prostática benigna (bph) ou cáncer de próstata nos homens
ES07734629.4T ES2551690T3 (es) 2006-05-22 2007-05-22 Método de tratamiento de la prostatitis crónica no bacteriana con moduladores selectivos del receptor de estrógeno o inhibidores de aromatasa
MX2008014825A MX2008014825A (es) 2006-05-22 2007-05-22 Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
EP07734629.4A EP2029128B1 (en) 2006-05-22 2007-05-22 Method of treatment of chronic nonbacterial prostatitis with selective estrogen receptor modulators or aromatase inhibitors
RU2008150489/15A RU2480207C2 (ru) 2006-05-22 2007-05-22 Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
NO20084822A NO341185B1 (no) 2006-05-22 2008-11-18 Anvendelse av fispemifene for fremstilling av et medikament for behandling av kronisk ikke-bakteriell prostatitt hos menn.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80265706P 2006-05-22 2006-05-22
US60/802,657 2006-05-22

Publications (2)

Publication Number Publication Date
WO2007135547A2 true WO2007135547A2 (en) 2007-11-29
WO2007135547A3 WO2007135547A3 (en) 2008-02-07

Family

ID=38610674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001321 Ceased WO2007135547A2 (en) 2006-05-22 2007-05-22 Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis

Country Status (13)

Country Link
US (1) US7825107B2 (enExample)
EP (1) EP2029128B1 (enExample)
JP (1) JP5123935B2 (enExample)
KR (1) KR101505884B1 (enExample)
CN (1) CN101448490A (enExample)
AU (1) AU2007252991B2 (enExample)
BR (1) BRPI0712103A2 (enExample)
CA (1) CA2652783C (enExample)
ES (1) ES2551690T3 (enExample)
MX (1) MX2008014825A (enExample)
NO (1) NO341185B1 (enExample)
RU (1) RU2480207C2 (enExample)
WO (1) WO2007135547A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
USD779449S1 (en) 2014-10-01 2017-02-21 Samsung Electronics Co., Ltd. Portable electronic device
USD781275S1 (en) 2014-10-01 2017-03-14 Samsung Electronics Co., Ltd. Portable electronic device
USD784972S1 (en) 2014-10-01 2017-04-25 Samsung Electronics Co., Ltd. Portable electronic device
USD795855S1 (en) 2014-10-01 2017-08-29 Samsung Electronics Co., Ltd. Portable electronic device
USD779450S1 (en) 2014-10-01 2017-02-21 Samsung Electronics Co., Ltd. Portable electronic device
USD803818S1 (en) 2014-10-01 2017-11-28 Samsung Electronics Co., Ltd. Portable electronic device
USD785586S1 (en) 2014-10-01 2017-05-02 Samsung Electronics Co., Ltd. Portable electronic device
USD797713S1 (en) 2014-10-01 2017-09-19 Samsung Electronics Co., Ltd. Portable electronic device

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) 1962-09-13
US4656187A (en) 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US4869155A (en) * 1988-07-11 1989-09-26 The Grieve Corporation Airflow distribution system for discharging air from a thin plenum, and oven employing same
US4977906A (en) 1989-03-07 1990-12-18 Scipio William J Di Diurnal rehabilitation for incontinence trainer
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5219548A (en) 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
EP0551434B1 (en) 1990-10-01 1995-11-15 The Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
US6096874A (en) 1990-10-01 2000-08-01 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5446203A (en) 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
GB2273704B (en) 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
RU2077889C1 (ru) * 1993-02-24 1997-04-27 Малое государственное предприятие "Флора" Способ лечения хронического простатита
DE4335876A1 (de) 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5658931A (en) 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
FI972235A7 (fi) 1994-11-29 1997-05-27 Hoechst Marion Roussel Inc Inc Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin h oidossa ja ehkäisyssä
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
GB9509572D0 (en) 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
DE19526146A1 (de) 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EA001103B1 (ru) 1996-01-29 2000-10-30 Эли Лилли Энд Компани Способы повышения компетенции сфинктера
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
AU4421697A (en) 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
GB9803521D0 (en) 1998-02-19 1998-04-15 Orion Yhtymo Oy New compounds and pharmaceutical compositions thereof
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413535B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO1999066915A2 (en) * 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Therapeutic applications of estrogenic carboxylic acids
CA2367895A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
RU2184543C1 (ru) * 2001-05-24 2002-07-10 Московская медицинская академия им. И.М.Сеченова Способ лечения хронического простатита
JP4301763B2 (ja) * 2001-10-31 2009-07-22 藤倉化成株式会社 銀化合物ペースト
US20030118633A1 (en) 2001-11-09 2003-06-26 Ebrahim Versi Combination therapy
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms

Also Published As

Publication number Publication date
RU2480207C2 (ru) 2013-04-27
JP2009537629A (ja) 2009-10-29
NO20084822L (no) 2008-12-15
CN101448490A (zh) 2009-06-03
EP2029128A2 (en) 2009-03-04
US7825107B2 (en) 2010-11-02
AU2007252991B2 (en) 2012-08-02
MX2008014825A (es) 2008-12-01
WO2007135547A3 (en) 2008-02-07
EP2029128B1 (en) 2015-08-05
CA2652783A1 (en) 2007-11-29
KR20090027640A (ko) 2009-03-17
BRPI0712103A2 (pt) 2012-01-17
KR101505884B1 (ko) 2015-03-25
JP5123935B2 (ja) 2013-01-23
CA2652783C (en) 2015-07-14
ES2551690T3 (es) 2015-11-23
US20080021111A1 (en) 2008-01-24
NO341185B1 (no) 2017-09-04
RU2008150489A (ru) 2010-06-27
AU2007252991A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US7825107B2 (en) Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors
AU2010257419B2 (en) Method for the treatment or prevention of lower urinary tract symptoms
JP6025301B2 (ja) 治療上の使用のためのｃ−１９ステロイド
KR20100117081A (ko) 양성 전립선 비대증, 전립선염, 전립선증 및 전립선 암 치료용 조성물
WO2003090753A1 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
Sachdeva et al. Stroma-mediated expression of estrogen and its role in cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018435.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734629

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007252991

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2652783

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/014825

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009511598

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007252991

Country of ref document: AU

Date of ref document: 20070522

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007734629

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008150489

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0712103

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081121